MUC1 and neoplasm: Moreover, tumor vaccine trials using a widely expressed shared antigen (MUC1) in patients with colorectal adenoma showed that over 50% of patients did not respond to the vaccine, which correlated with high numbers of circulating MDSC [160], revealing that interference with anti-tumor immune responses may develop already at the pre-cancerous stage.